Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01301443 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
A Phase 1 study, sponsored by Oxford BioMedica.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01301443 is a Phase 1 study that has completed, run by Oxford BioMedica. The registered enrollment target is 21 participants.
The verdict
NCT01301443, a Phase 1 study, has completed, sponsored by Oxford BioMedica.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.
Interventions
- DRUG Subretinally injected RetinoStat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01301443
The ClinicalTrials.gov registry entry for NCT01301443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oxford BioMedica, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subretinally injected RetinoStat is the first listed.
NCT01301443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01301443 about?
NCT01301443 is a clinical study titled "Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)". The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.
What is the current status of trial NCT01301443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01301443?
The interventions under investigation include: Subretinally injected RetinoStat (DRUG).
Who is sponsoring clinical trial NCT01301443?
This trial is sponsored by Oxford BioMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.